Major multinationals open, close, open R&D centers in China

A timeline of moves by major multinationals to enter China's innovation ecosystem

After pulling back to reconsider their strategies, several pharmas are once again plunging into China’s life sciences innovation ecosystem, this time leaning more heavily on creation of innovation centers than R&D facilities.

The changes reflect the shifting landscape of the biopharma industry in China, and the problems MNCs have run up against since they started putting R&D footprints there in the 2000s. A common thread is that the behemoths have found it hard to go it alone, and built strategies around creating ties with the increasing number of innovative domestic companies.

Three waves characterize

Read the full 931 word article

How to gain access

Continue reading with a
two-week free trial.